MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Mazdutide

  • Home
  • Mazdutide
Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or Overweight
Posted inDiabetes & Endocrinology news

Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or Overweight

Posted by By MedXY 08/22/2026
Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.
Read More
  • Peripheral Parenteral Nutrition Reduces Inflammation and Enhances Nutritional Recovery After Colorectal Surgery: Insights from a Randomized Trial
  • AI-Driven 3D Liver Modeling Enhances Prediction of Liver Resection Complexity from Preoperative CT Scans
  • Evaluating the Effectiveness of Preoperative Patient Education on Opioid Use and Postoperative Pain Management: Insights from a Randomized Trial
  • Decoding Success: How Hospital Contexts Shape Enhanced Recovery Program Implementation
  • Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Evaluating Periconception Exposure and Perinatal Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular outcomes cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top